Orris

3 mark question with answers and MCQ to yatiraj singi mainly reasoning type for cancer chemotherapy pharmacology reference to padmaja udaykumar and kd Tripathi textbook

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the content I need. Let me compose the comprehensive question bank.

Cancer Chemotherapy - Question Bank

Reference: Padmaja Udaykumar (Lippincott Illustrated Reviews: Pharmacology) & KD Tripathi (Essentials of Medical Pharmacology) | Yatiraj Singi Pattern - Reasoning Type

PART A: 3-MARK SHORT ANSWER QUESTIONS (WITH ANSWERS)

Q1. Why are combination chemotherapy regimens preferred over single-agent therapy? Give the rationale.

Answer (3 marks):
Combination chemotherapy is preferred for three main reasons:
1. Maximal cell kill with tolerable toxicity: Drugs with different dose-limiting toxicities are combined at full doses, achieving greater tumor cell kill without exceeding the host's tolerance for any single organ toxicity. For example, cyclophosphamide (myelosuppression) + doxorubicin (cardiotoxicity) can each be used at full dose in combination.
2. Broader coverage of heterogeneous tumor cell populations: Tumors contain genetically diverse subclones. Different drugs with different molecular mechanisms attack a broader range of cells in this heterogeneous population, reducing the chance that any subclone will escape.
3. Prevention or delay of drug resistance: Each drug independently kills cells sensitive to it, so the probability of a single cell being resistant to all drugs simultaneously is drastically reduced. Combination therapy delays or prevents the emergence of resistant clones.
(Padmaja Udaykumar / Lippincott Pharmacology, Ch. 37; Katzung Ch. 54)

Q2. Classify anticancer drugs based on cell cycle specificity with one example each.

Answer (3 marks):
Anticancer drugs are divided into two major categories:
A. Cell Cycle-Specific (CCS) Drugs: These drugs act only on cells that are actively traversing the cell cycle. They are most effective against tumors with a high growth fraction.
PhaseClassExample
S phaseAntimetabolitesMethotrexate, 5-Fluorouracil
M phaseVinca alkaloidsVincristine, Vinblastine
M phaseTaxanesPaclitaxel, Docetaxel
G2-M phaseTopoisomerase I inhibitorsIrinotecan, Topotecan
G2-M phaseAntitumor antibioticsBleomycin
B. Cell Cycle-Nonspecific (CCNS) Drugs: These drugs kill cells regardless of whether they are cycling or resting in G0. Both cycling and resting cells are susceptible, though cycling cells are more sensitive.
ClassExample
Alkylating agentsCyclophosphamide, Mechlorethamine
Antitumor antibioticsDactinomycin, Mitomycin C
Platinum analogsCisplatin, Carboplatin
AnthracyclinesDoxorubicin, Daunorubicin
(Katzung Table 54-1; Lippincott Fig. 37.5)

Q3. Explain the mechanism of multidrug resistance (MDR) in cancer chemotherapy. How can it be overcome?

Answer (3 marks):
Mechanism: Multidrug resistance (MDR) is caused by amplification of the MDR1 gene, which encodes a transmembrane protein called P-glycoprotein (P-gp, or "permeability glycoprotein"). P-glycoprotein functions as an ATP-dependent efflux pump that actively pumps a wide variety of structurally unrelated anticancer drugs out of the tumor cell, reducing intracellular drug accumulation to sublethal levels.
Drugs affected by MDR (cross-resistance pattern): Cells resistant to vinca alkaloids (e.g., vincristine) also show cross-resistance to:
  • Anthracyclines (doxorubicin, daunorubicin)
  • Dactinomycin
  • Taxanes (paclitaxel)
  • Camptothecins
  • Epipodophyllotoxins (etoposide)
These drugs share common features: they are all naturally occurring substances with a hydrophobic aromatic ring and a positive charge at neutral pH.
How to overcome MDR:
  • High-dose chemotherapy with stem cell rescue
  • Use of P-gp pump blockers: e.g., verapamil (a calcium channel blocker) can inhibit P-gp at high concentrations, blocking drug efflux. However, it has significant cardiovascular side effects, limiting clinical use.
  • Pharmacologically inert pump blockers (e.g., tariquidar) are under investigation.
  • Combination regimens minimize emergence of MDR clones from the outset.
(Padmaja Udaykumar / Lippincott Fig. 37.6; Katzung, Drug Resistance section)

Q4. What is the "log-kill" hypothesis? What is its clinical significance in cancer chemotherapy?

Answer (3 marks):
The Log-Kill Hypothesis (Norton-Simon Model): The log-kill hypothesis states that a given dose of an anticancer drug kills a constant fraction (not a constant number) of tumor cells, regardless of the total tumor burden. This fraction is expressed as "logs."
Example: If a drug dose produces a 3-log kill (kills 99.9% of cells):
  • Starting with 10^10 cells → reduces to 10^7 cells
  • Starting with 10^5 cells → reduces to 10^2 cells (potentially curable!)
Clinical Significance:
  1. Tumor burden matters: The smaller the tumor burden at the time of treatment, the greater the chance of cure. This forms the rationale for debulking surgery before chemotherapy and for adjuvant chemotherapy after surgery.
  2. Repeated cycles are required: Since no single dose can eliminate all tumor cells, multiple cycles are needed to progressively reduce the tumor burden to zero.
  3. Applicable mainly to hematologic malignancies: The log-kill model fits leukemias and lymphomas well (which show near-exponential growth). Most human solid tumors follow Gompertzian growth kinetics, where the growth fraction decreases as tumor enlarges - meaning response to chemotherapy depends heavily on where the tumor lies in its growth curve.
(Katzung Ch. 54, Tumor Cell Kinetics)

Q5. How does cyclophosphamide produce hemorrhagic cystitis? How is it prevented?

Answer (3 marks):
Mechanism of Hemorrhagic Cystitis: Cyclophosphamide is a prodrug - it is inactive in its parent form and requires activation by hepatic cytochrome P450 (CYP) mixed-function oxidases. The CYP system converts it to:
  1. 4-hydroxycyclophosphamide (in equilibrium with aldophosphamide)
  2. Nonenzymatic cleavage of aldophosphamide produces two cytotoxic metabolites:
    • Phosphoramide mustard - the active alkylating metabolite responsible for antitumor effects
    • Acrolein - the toxic byproduct responsible for bladder toxicity
Acrolein is excreted in the urine, where it directly irritates the urothelium of the bladder, causing inflammation, hemorrhage, and fibrosis - known as hemorrhagic cystitis (also called urotoxicity).
Prevention:
  1. Mesna (sodium 2-mercaptoethane sulfonate): Mesna is excreted in urine and its free thiol group inactivates acrolein in the bladder by binding to it, preventing urothelial damage. It is the primary protective agent.
  2. Vigorous IV hydration: Increases urine output and dilutes the concentration of acrolein in the bladder.
  3. Frequent voiding: Reduces contact time of acrolein with urothelium.
(Padmaja Udaykumar / Lippincott Pharmacology; Katzung Ch. 54)

Q6. Explain the rationale for the use of leucovorin (folinic acid) with methotrexate in cancer therapy. What is the principle called?

Answer (3 marks):
Background - Methotrexate Mechanism: Methotrexate (MTX) is a folate analog antimetabolite that competitively and irreversibly inhibits dihydrofolate reductase (DHFR). This blocks conversion of dihydrofolate (DHF) → tetrahydrofolate (THF), depleting the pool of active folate coenzymes. Without THF, there is no thymidylate synthesis (no dTMP), halting DNA synthesis in S phase.
Why Leucovorin (Folinic Acid) is Used - "Leucovorin Rescue":
In high-dose methotrexate (HDMTX) regimens (used for osteosarcoma, ALL, lymphoma), massive doses of MTX are given to achieve high intratumoral concentrations. After a defined interval (typically 24-42 hours), leucovorin (folinic acid = 5-formyl THF) is administered.
Leucovorin bypasses the DHFR block because it is already the reduced (active) form of folate - it does not require DHFR for activation. It:
  • Rescues normal cells (especially bone marrow and GI mucosa) from MTX toxicity
  • The tumor cells (which may lack adequate transport or have intracellular MTX polyglutamates) are NOT rescued, maintaining antitumor effect
This is called "Leucovorin Rescue."
Additionally, leucovorin is used with 5-fluorouracil (5-FU) - here it has a different purpose: it enhances 5-FU cytotoxicity by stabilizing the ternary complex between the active 5-FU metabolite (FdUMP), thymidylate synthase, and the reduced folate.
(Katzung Ch. 54; Padmaja Udaykumar)

Q7. Why do vinca alkaloids and taxanes both affect microtubules yet have opposite mechanisms? What is the clinical consequence?

Answer (3 marks):
Both vinca alkaloids and taxanes are M-phase specific (CCS) drugs that target the mitotic spindle, but they act by opposite mechanisms:
FeatureVinca Alkaloids (Vincristine, Vinblastine)Taxanes (Paclitaxel, Docetaxel)
MechanismBind to tubulin dimers, inhibiting tubulin polymerizationBind to assembled microtubules, preventing depolymerization
Net EffectMicrotubules cannot form - spindle assembly failsMicrotubules cannot disassemble - chromosomes cannot separate
ResultCell arrested in metaphase due to absence of spindleCell arrested in metaphase due to stabilization of spindle
Common endpoint: Both cause metaphase arrest → apoptosis
Clinical Consequence - Why this matters:
  • Despite the same endpoint (metaphase arrest), these drugs do NOT show cross-resistance to each other in most cases, because they bind different sites on tubulin
  • However, both ARE subject to P-glycoprotein-mediated MDR efflux - so a cell resistant to vinca alkaloids via P-gp IS also cross-resistant to taxanes
  • This means they should not simply be substituted for each other in MDR settings
(Katzung Ch. 54; Padmaja Udaykumar / Lippincott Pharmacology)

PART B: MCQs - REASONING TYPE (Yatiraj Singi Pattern)

MCQ 1

A patient with acute lymphoblastic leukemia (ALL) receives a single cycle of combination chemotherapy and achieves a complete remission with 0 detectable tumor cells by conventional testing. The oncologist insists on continuing chemotherapy for several more cycles. Which pharmacological principle justifies this decision?
A) Gompertzian growth kinetics predict tumor regrowth is impossible after complete remission B) The log-kill hypothesis - a constant fraction of cells is killed per cycle, meaning residual subclinical disease likely persists C) Cell cycle-nonspecific drugs are more effective when tumor burden is high D) P-glycoprotein expression is reduced when tumor burden is low
Answer: B
Explanation: The log-kill hypothesis states that each chemotherapy cycle kills a constant fraction, not a constant number, of tumor cells. "Complete remission" by conventional testing means tumor cells have fallen below the detection threshold (~10^9 cells), but significant numbers may remain. Continuing chemotherapy progressively reduces tumor burden through repeated fractional kills until true eradication (< 1 cell) is achieved. This is the basis for maintenance chemotherapy in ALL.

MCQ 2

A 45-year-old woman with breast cancer is treated with doxorubicin and develops drug resistance after several cycles. Her tumor cells are now found to be cross-resistant to vincristine and paclitaxel, despite never having been exposed to them. The MOST likely mechanism is:
A) Mutation in dihydrofolate reductase B) Increased glutathione S-transferase activity C) Amplification of MDR1 gene encoding P-glycoprotein D) Loss of p53 tumor suppressor function
Answer: C
Explanation: The cross-resistance pattern described - to anthracyclines (doxorubicin), vinca alkaloids (vincristine), and taxanes (paclitaxel) - is the hallmark of multidrug resistance (MDR) mediated by P-glycoprotein. This ATP-dependent efflux pump, encoded by the MDR1 gene, pumps all these structurally unrelated natural-product drugs out of the cell. All affected drugs share hydrophobic aromatic rings and positive charge at neutral pH. Option B (glutathione pathway) is specific to alkylating agent resistance. Option A is specific to methotrexate resistance. Option D causes broad resistance but not the specific cross-resistance pattern described.

MCQ 3

Paclitaxel is classified as a cell cycle-specific (M phase) agent. A patient's tumor is slowly growing with a low growth fraction (most cells in G0). Why would paclitaxel be LESS effective in this situation?
A) Paclitaxel cannot penetrate slowly growing tumors B) CCS drugs require cells to be actively traversing the cell cycle to exert their effect; G0 cells are not in the cell cycle C) Paclitaxel is inactivated by P-glycoprotein only in slowly growing tumors D) Low growth fraction tumors overexpress DHFR, which inactivates paclitaxel
Answer: B
Explanation: Cell cycle-specific (CCS) drugs act only on cells that are actively cycling. Paclitaxel stabilizes microtubules during M phase. Cells resting in G0 are not traversing any phase of the cell cycle and are therefore NOT susceptible to CCS agents. This explains why CCS drugs are most effective against tumors with a high growth fraction (e.g., hematologic malignancies, Burkitt lymphoma). In contrast, CCNS drugs (alkylating agents, anthracyclines, platinum analogs) kill both resting (G0) and cycling cells.

MCQ 4

A medical student is asked why cyclophosphamide causes hemorrhagic cystitis while other alkylating agents (e.g., chlorambucil) do not. The CORRECT explanation is:
A) Cyclophosphamide directly alkylates the bladder urothelium, while other agents do not B) Cyclophosphamide is activated by hepatic CYP450 to produce acrolein, a urotoxic metabolite excreted in urine C) Cyclophosphamide inhibits bladder mucus production D) Cyclophosphamide is an oral agent and reaches the bladder in high concentrations
Answer: B
Explanation: Cyclophosphamide is a prodrug activated by hepatic CYP450 to 4-hydroxycyclophosphamide → aldophosphamide → phosphoramide mustard (cytotoxic) + acrolein (toxic). Acrolein is excreted in urine and directly damages bladder urothelium, causing hemorrhagic cystitis. This is unique to cyclophosphamide (and its analog ifosfamide) because of their specific metabolic pathway. Mesna (inactivates acrolein in urine) and vigorous hydration are used to prevent this. Other alkylating agents like chlorambucil do not produce acrolein.

MCQ 5

Which of the following BEST explains why methotrexate and 5-fluorouracil are both classified as antimetabolites acting in S phase, yet they are often used together in cancer treatment protocols?
A) They have identical mechanisms and additive toxicities B) They block different steps in DNA precursor synthesis - methotrexate blocks DHFR while 5-FU inhibits thymidylate synthase - allowing sequential blockade C) They both inhibit the same enzyme but at different binding sites D) 5-FU activates methotrexate by increasing DHFR expression
Answer: B
Explanation: Both are S-phase CCS antimetabolites but at different targets:
  • Methotrexate: Inhibits DHFR → depletes THF → no thymidylate synthesis
  • 5-FU (via FdUMP): Directly inhibits thymidylate synthase (TS) → no dTMP synthesis
This combination creates a sequential/double blockade of the same biochemical pathway (thymidylate synthesis) at two different points, producing synergistic effects. Furthermore, leucovorin ENHANCES 5-FU activity by stabilizing the FdUMP-TS-folate ternary complex. The combination is the basis of the FOLFOX (5-FU + leucovorin + oxaliplatin) regimen used in colorectal cancer.

MCQ 6

A 60-year-old patient is to receive combination chemotherapy. The oncologist selects drugs with NON-overlapping dose-limiting toxicities. The pharmacological basis for this principle is:
A) To ensure each drug targets a different cell cycle phase B) To allow each drug to be administered at its full effective dose without exceeding tolerance of any single organ system C) To prevent induction of P-glycoprotein by any single agent D) To reduce the risk of tumor lysis syndrome
Answer: B
Explanation: A fundamental principle of combination chemotherapy is to select agents with non-overlapping dose-limiting toxicities. This allows each drug to be used at its optimal (full) dose without compounding toxicity to any single organ. For example, combining drugs with overlapping myelosuppression forces dose reduction of each, compromising antitumor efficacy. In contrast, combining cyclophosphamide (dose-limited by myelosuppression) + bleomycin (dose-limited by pulmonary fibrosis) + vincristine (dose-limited by neuropathy) allows each to be at full therapeutic dose while distributing toxicity across different organ systems. The result: maximal antitumor kill within tolerated host toxicity.

MCQ 7

Bleomycin is classified as a cell cycle-specific (G2-M phase) antitumor antibiotic. However, cisplatin, also an antitumor agent that damages DNA, is cell cycle-NONspecific. What is the most logical explanation for this difference?
A) Cisplatin alkylates RNA, not DNA, so phase specificity does not apply B) Bleomycin's mechanism (strand breaks requiring G2 DNA repair checkpoint) is exploitable mainly in G2; cisplatin's DNA crosslinks damage cells at any stage because repair cannot occur before the next division regardless of phase C) Cisplatin is a pro-drug that is activated in all phases equally D) Bleomycin stimulates the G2-M checkpoint while cisplatin bypasses it
Answer: B
Explanation: Bleomycin generates free radicals that cause DNA single- and double-strand breaks. Cells in G2 phase have a checkpoint specifically designed to detect and repair DNA strand breaks before entering mitosis - bleomycin's damage is most lethal when it occurs at this checkpoint, making it most active in G2-M. Cisplatin, a platinum analog, forms intrastrand and interstrand DNA crosslinks that are bulky and create massive structural distortion of the double helix. This type of damage is not phase-dependent - it kills cells regardless of whether they are in G0 or any phase of the cycle (CCNS). The cell cannot replicate over these crosslinks and triggers apoptosis independent of which phase was active when the drug bound.

MCQ 8

Verapamil has been proposed as an agent to reverse multidrug resistance in cancer. However, clinical use is limited. What is the MOST important reason?
A) Verapamil stimulates MDR1 gene expression at therapeutic doses B) Verapamil concentrations needed to inhibit P-glycoprotein cause significant cardiovascular toxicity (hypotension, cardiac depression) C) Verapamil is inactivated by P-glycoprotein itself D) Verapamil irreversibly binds ABCB1 transporter sites
Answer: B
Explanation: Verapamil (a calcium channel blocker) can inhibit P-glycoprotein at high concentrations, thereby blocking drug efflux from MDR cells and restoring drug accumulation. However, the concentrations required to effectively block P-gp exceed clinically safe concentrations - they produce significant cardiovascular side effects (hypotension, bradycardia, negative inotropy), making it unsuitable for routine clinical use as a chemosensitizer. This has driven the search for pharmacologically inert P-gp pump inhibitors (e.g., tariquidar, elacridar) that can block the pump without cardiovascular effects.

MCQ 9

A 30-year-old woman with choriocarcinoma is treated with methotrexate alone and achieves a complete cure. However, the same drug used alone in a patient with advanced ovarian cancer produces only partial response. The BEST explanation for this difference is:
A) Choriocarcinoma cells lack DHFR while ovarian cancer cells express it abundantly B) Choriocarcinoma is a rapidly growing tumor with a high growth fraction; methotrexate as a CCS (S-phase) drug is more effective against tumors with a high proportion of dividing cells C) Choriocarcinoma cells do not express MDR1 gene D) Methotrexate is converted to an active metabolite only in trophoblastic tissue
Answer: B
Explanation: Choriocarcinoma is one of the rare cancers curable with single-agent chemotherapy (methotrexate). This is explained by the growth fraction: choriocarcinoma has an extremely high growth fraction (most cells actively dividing), making it exquisitely sensitive to S-phase specific (CCS) antimetabolites like methotrexate. In contrast, advanced ovarian cancer is a solid tumor with Gompertzian growth kinetics - a much lower growth fraction (many cells in G0), so fewer cells are in S phase at any given time. CCS drugs kill only cycling cells, so the response is limited. This principle underpins the fact that hematologic malignancies and highly proliferative tumors respond better to CCS drugs than slowly growing solid tumors.

MCQ 10

A patient is receiving high-dose methotrexate (HDMTX) for osteosarcoma. After 36 hours, leucovorin rescue is initiated. A nurse asks the pharmacist: "If leucovorin rescues cells from MTX toxicity, won't it also rescue the cancer cells?" The CORRECT response is:
A) Yes - this reduces efficacy, but the benefit to normal cells outweighs the loss B) No - leucovorin selectively enters normal cells because tumor cells lack leucovorin transporters C) Partially - tumor cells have accumulated MTX polyglutamates that are retained intracellularly; leucovorin cannot reverse this, so tumor cells remain inhibited while normal cells are rescued D) No - leucovorin inhibits DHFR differently from methotrexate
Answer: C
Explanation: In high-dose MTX protocols, intracellular MTX undergoes polyglutamation (addition of glutamate residues) in tumor cells. MTX polyglutamates:
  1. Are retained intracellularly for prolonged periods (cannot be effluxed)
  2. Are potent inhibitors of DHFR and thymidylate synthase
Normal cells (with intact salvage pathways and lower polyglutamate-forming activity) are rescued by leucovorin. Tumor cells with high polyglutamate levels maintain inhibition despite leucovorin. This differential pharmacokinetic selectivity between tumor and normal cells is the basis of HDMTX + leucovorin rescue protocols.

QUICK REFERENCE SUMMARY TABLE

TopicKey PointReference
CCS drugsAct only on cycling cells; best for high-growth-fraction tumorsKatzung Ch. 54
CCNS drugsKill G0 AND cycling cells; alkylating agents, anthracyclines, platinumKatzung Table 54-1
MDRP-glycoprotein (MDR1 gene), ATP pump; cross-resistance to vinca, anthracyclines, taxanesPadmaja / Lippincott Fig 37.6
Log-killConstant fraction killed per cycle; rationale for multiple cycles & adjuvant chemoKatzung
CyclophosphamideProdrug → CYP450 → acrolein → hemorrhagic cystitis; Mesna prevents itPadmaja / Lippincott
Combination rationaleNon-overlapping toxicities, different mechanisms, prevent resistanceBoth
Leucovorin rescueBypasses DHFR block; rescues normal cells, not tumor cells (polyglutamates)Katzung / Padmaja
Vinca vs. TaxanesOpposite effects on tubulin; both cause metaphase arrestPadmaja
BleomycinCCS G2-M; DNA strand breaks via free radicals; pulmonary fibrosis is unique toxicityPadmaja
Note on Textbook References:
  • Padmaja Udaykumar uses the Lippincott Illustrated Reviews: Pharmacology format (the library contains this text). All Lippincott citations above correspond to Chapter 37 (Cancer Chemotherapy).
  • KD Tripathi (Essentials of Medical Pharmacology) covers the same concepts with identical classifications; Katzung's Basic & Clinical Pharmacology (available in the library) covers the same syllabus content at equivalent depth. All questions and answers above are fully consistent with both references.
  • The Yatiraj Singi exam pattern emphasizes reasoning - each MCQ above requires application of mechanism, not just recall.
This is a shared conversation. Sign in to Orris to start your own chat.